Joshua A. Vieth, PhD

Joshua Vieth, Ph.D., is senior director of research at Breakthrough T1D, responsible for Disease-Modifying Therapies. With expertise in immunology, organizational development, and scientific communication, he received his B.S. in biology from Baldwin Wallace University and a Ph.D. in infection, immunity, and transplant science at the University of Toledo College of Medicine. He completed his postdoctoral fellowship at the Memorial Sloan Kettering Cancer Center and the Child Health Institute at Rutgers University. Joshua’s research interests focused on the development of rare T cell subsets and included the discovery that non-ligand binding domains of the T cell receptor are critical for the development and function of natural killer T (NKT) cell populations. Prior to joining Breakthrough T1D, he was Managing Director of the Immune Monitoring and Advanced Genomics Facility at the Cancer Institute of New Jersey. Joshua spends his free time focused on several causes, including numerous local boards and commissions and serving as President of the Board of Directors of the Morris Animal Refuge in Philadelphia, Pennsylvania.